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ABSTRACT
Background: Indacaterol is an investigational, novel, inhaled once-daily ultra-long-acting beta-2 agonist for
the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the 24-h bronchodilatory
efficacy and safety of indacaterol in Japanese patients with COPD.
Methods: This Phase-II, randomised, placebo-controlled, crossover study comprised four double-blind,
single-dose treatment periods (washout between periods: 14-28 days). Japanese patients aged 40-75 years
with moderate-to-severe COPD were randomised to receive single doses of indacaterol (150, 300, or 600 μg)
or placebo via a single-dose dry-powder inhaler. Efficacy (primary endpoint: standardised FEV1AUC22-24h) and
safety were assessed for 24 h post-dose in each treatment period.
Results: Of the 50 patients randomised (92% male; mean age, 67.2 years), 45 completed the study. Stan-
dardised FEV1AUC22-24h was significantly higher for all indacaterol doses as compared with placebo, with clini-
cally relevant differences of 130, 160, and 170 mL for 150, 300, and 600 μg, respectively (P < 0.001). The im-
provement in FEV1 was seen as early as 5 min post-dose with indacaterol and sustained for 24 h (P < 0.001 vs
placebo at all time points). All indacaterol doses were well tolerated and showed no clinically meaningful effect
on pulse rate, blood pressure, QTc interval, and laboratory parameters when compared with placebo.
Conclusions: In the Japanese COPD population studied, single doses of indacaterol (150, 300, and 600 μg)
provided sustained 24-h bronchodilation, with onset of action within 5 min post-dose. All doses were well toler-
ated. These results are consistent with data from Caucasian populations.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
one of the leading causes of morbidity and mortality
worldwide, accounting for a loss of approximately 30
million disability-adjusted life years in 2001.1 The
prevalence of COPD in Japan in adults aged 40
years is estimated to be at least 8.6%.2 The increase in
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global COPD prevalence and mortality is anticipated
to continue, with the disease being predicted to be-
come the third leading cause of death worldwide, af-
ter heart disease and stroke, by 2020 (8.6% of all
deaths).3,4
COPD is characterised by airflow limitation caused
by an abnormal inflammatory response in the lung.
This airflow limitation is usually progressive and not
fully reversible.5 According to the Guidelines for the
Diagnosis and Treatment of COPD issued by the
Japanese Respiratory Society (JRS),6 and the Global
Initiative for Chronic Obstructive Lung Disease
guideline for COPD Diagnosis, Management, and
Prevention (GOLD)5 bronchodilators such as beta2-
agonists and anticholinergics are central to the symp-
tomatic management of COPD. By altering airway
smooth muscle tone, bronchodilators improve expira-
tory flow, reduce dynamic hyperinflation at rest and
during exercise, and improve exercise perform-
ance.5,7,8 Regular use of long-acting bronchodilators
has been shown to be more effective and convenient
than treatment with short-acting bronchodilators.9-12
Currently available inhaled long-acting beta2-agonists
(LABAs), such as salmeterol and formoterol, induce
bronchodilation that lasts for approximately 12 h and
are administered twice daily.13-16
Indacaterol is a novel, once-daily, inhaled ultra-
LABA17 currently in development for the treatment of
COPD. The efficacy and safety of once-daily dosing of
indacaterol in COPD patients have already been dem-
onstrated in several studies that involved mostly the
Caucasian population.18-20 This is the first study evalu-
ating the effect of indacaterol in Japanese patients
with COPD, and given its similarity to a study con-
ducted in a Caucasian population it helps to evaluate
the ethnic sensitivity of the efficacy and safety of inda-
caterol.20
The aim of the present randomised, double-blind,
placebo-controlled study was to examine the 24-h
bronchodilatory efficacy of a single dose of inda-
caterol 150, 300, and 600 μg, administered via a
single-dose dry powder inhaler (SDDPI) in Japanese
patients with COPD.
METHODS
This was a multicentre, randomised, double-blind,
placebo-controlled, crossover, dose-ranging, Phase II
study conducted between December 2006 and Octo-
ber 2007 at 11 specialised respiratory care units in Ja-
pan (ClinicalTrials.gov registration no.: NCT
00403845).21 The study was approved by the institu-
tional review board of each participating study centre
and was conducted in accordance with the Interna-
tional Conference on Harmonisation guidelines for
Good Clinical Practice, applicable local regulations,
and the ethical principles embodied in the Declara-
tion of Helsinki. Written informed consent was ob-
tained from each patient before their participation in
the study.
STUDY POPULATION
Eligible for enrolment were male and female Japa-
nese patients aged 40-75 years with clinically diag-
nosed COPD (according to the JRS Guideline for the
Diagnosis and Treatment of COPD),6 a smoking his-
tory of 20 pack years, post-bronchodilator forced
expiratory volume in 1 second (FEV1)forced vital ca-
pacity (FVC) <70%, and FEV1 30% but <80% of pre-
dicted normal value at screening. Patients were ex-
cluded from the study if they had a history of heart
failure, myocardial infarction, or asthma; had been
hospitalised for a COPD exacerbation in the 6
months prior to screening; or had experienced a res-
piratory tract infection within 1 month prior to screen-
ing.
STUDY DESIGN AND TREATMENTS
The study comprised a 14-day screening period, dur-
ing which patients were assessed for eligibility and
monitored to ensure that they remained stable on
their permissible COPD treatment. The screening pe-
riod was followed by a randomised, double-blind
treatment period (Fig. 1). At baseline, eligible pa-
tients were randomised equally to one of four treat-
ment sequences (each with four double-blind treat-
ment periods, with each patient receiving each of the
four different treatments―one in each treatment pe-
riod). Randomisation was performed using a vali-
dated system that automated the random assignment
of the treatment sequences to randomisation num-
bers.
On Day 1 of each treatment period (Visits 2, 4, 6,
and 8), patients received a single dose of indacaterol
150, 300, or 600 μg or placebo via an SDDPI (taken
between 08 : 00 and 10 : 00 AM) according to the as-
signed treatment sequence. Each treatment period
was separated by a washout period of 14-28 days.
Treatment allocation was concealed from the pa-
tients, investigating staff, and the clinical trial team by
using study drugs of identical packaging, labelling,
schedule of administration, and appearance.
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CONCOMITANT MEDICATION
Allowable therapy included the use of inhaled corti-
costeroids, provided the regimen had been stabilised
for at least 1 month prior to the screening visit and
the same regimen was continued for the duration of
the study. The following medications could not be
used prior to screening or administration of study
drug on Day 1 in each treatment period for at least
the minimum washout period specified, as indicated
within the parentheses: the long-acting anticholiner-
gic tiotropium (7 days), short-acting anticholinergics
(8 h), short-acting beta2-agonists (6 h), LABAs (48
h), and xanthine derivatives (48 h). Salbutamol was
the only rescue medication permitted throughout the
study, although the visits had to be rescheduled if it
was taken within 6 h prior to the first spirometry
measurements during that visit.
ASSESSMENTS
Efficacy and safety were assessed for 24 h post-dose
in each treatment period. Efficacy was assessed by
spirometry using the same model of spirometer (MI-
CROSPIRO HI-201Ⓡ, Nihon Kohden Corporation, To-
kyo, Japan) in all patients. FEV1, FVC, and forced ex-
piratory flow 25% to 75% (FEF25-75%) were determined
pre-dose (15 min prior to inhalation) and at 5, 15, and
30 min and 1, 2, 4, 8, 12, 22, 23, and 24 h post-dose.
The primary efficacy outcome was the time-
standardised area under the curve (AUC) of FEV1
values measured between 22 and 24 h post-dose
(FEV1AUC22-24h; L), calculated using the trapezoidal
rule and adjusted for the area per time unit by using
the scheduled time of measurements for FEV1. Sec-
ondary efficacy outcomes included percent change in
FEV1 from baseline at individual post-dose time
points; peak FEV1 (defined as the maximum FEV1
value recorded between 5 min and 4 h post-dose);
standardised FEV1AUC0-24h, and individual time-point
FEV1, FVC, and FEF25-75%.
Safety assessments involved recording of all ad-
verse events (AEs) and serious adverse events
(SAEs); monitoring of haematology and blood bio-
chemistry at regular time points in each treatment pe-
riod; urinalysis; and regular assessments of vital
signs, electrocardiogram (ECGs), physical condition,
and body weight.
SAMPLE SIZE CALCULATION AND STATISTI-
CAL ANALYSES
The three main treatment comparisons in this study
were indacaterol 150 μg versus placebo, indacaterol
300 μg versus placebo, and indacaterol 600 μg versus
placebo. A sample size of approximately 40 patients
was estimated prior to the study, assuming a minimal
clinically important difference of 120 mL between
each indacaterol dose and placebo in terms of stan-
dardised FEV1AUC22-24h,22,23 a standard deviation of
220 mL,18 a two-sided significance level of 10% (ad-
justed to 3.3% using a Bonferroni correction for the
three main treatment comparisons), and a power of
85%. Allowing for a 15% dropout rate and with the
number inflated to ensure balance across the treat-
ment sequences, it was calculated that 48 patients
were to be randomised.
The primary efficacy analysis was performed on a
modified intention-to-treat (mITT) population, which
included all randomised patients who received at
least one dose of study drug and had post-
randomisation efficacy data. Patients receiving only
one treatment did not contribute to the analyses of
treatment contrasts, although they remained in the
population for the calculation of individual treatment
means. All patients who received at least one dose of
study drug were included in the safety population,
which was used in the analysis of all safety variables.
The safety population allowed for the inclusion of
non-randomised patients who might have received
the study drug in error. For both populations, pa-
tients were analysed according to the treatment re-
ceived. Demographic and baseline characteristics
were summarised for all patients in the safety popula-
tion.
The primary efficacy variable, standardised FEV1
AUC22-24h, was calculated using the trapezoidal rule
and was adjusted for the area per time unit by using
the scheduled time of measurements for FEV1. Treat-
ment differences between each indacaterol dose and
placebo were tested using analysis of covariance (AN-
COVA), with patient, period, and treatment group
modelled as fixed effects and period baseline FEV1 as
a covariate. Period baseline FEV1 was defined as the
value measured prior to the inhalation of study drug
in each treatment period. Adjustment for multiple
comparisons was made using a stepwise Dunnett test
implemented via a closed test procedure. Similar AN-
COVA models were used to analyse all secondary effi-
cacy variables. Laboratory data for haematology,
blood biochemistry, and urinalysis; ECG data; and
measurements of vital signs were summarised de-
scriptively by treatment group. The corrected QT in-
terval was calculated from the QT and RR intervals
using Fridericia’s formula (QTcF).24,25 All tests of hy-
potheses used were two-tailed and interpreted at the
10% significance level (as this was a dose-ranging
Phase II study). The data were analysed using SAS
statistical software version 8.2 (or higher) for Win-
dows (SAS Institute Inc., Cary, North Carolina, USA).
RESULTS
PATIENT DISPOSITION, DEMOGRAPHICS, AND
BASELINE CHARACTERISTICS
Out of 84 patients screened, 50 were randomised.
The most common reason for failing to meet the eligi-
bility criteria was unacceptable test results, mainly
with respect to spirometry and laboratory findings
Kato M et al.











































Fig. 2 Standardised FEV1AUC22-24h least squares means 
(±SE) (modified intent-to-treat population). AUC, area under 
the curve; FEV1, forced expiratory volume in 1 second; SE, 
standard eror. *P < 0.001 vs. placebo; **P < 0.05 vs. inda-
caterol 150 μg.
Table 1 Patient demographics and baseline characteristics (safety population)
Total (N = 50)StatisticParameter
(5.94)67.2 Mean (SD)Age, years
48-75Range
Sex, n (%) 
(92.0)46 Male 
(8.0) 4 Female 
(10.05)57.5 Mean (SD)Weight, kg 
(3.09)21.6 Mean (SD)Body mass index, kg/m2 
(3.69) 2.9 Mean (SD)Duration of COPD, years 
0.02-17.03Range
(0.395)1.46 Mean (SD)FEV1 (post-bronchodilator) at screening, L 
(13.82)53.2 Mean (SD)% predicted FEV1 (post-bronchodilator) at screening 
31.3-77.8Range
(9.62)12.06 Mean (SD)FEV1 reversibility at screening, % 
(0.686)3.07 Mean (SD)FVC (post-bronchodilator) at screening, L
(11.28)48.2 Mean (SD)FEV1/FVC (post-bronchodilator) at screening, % 
Smoking History, n (%) 
(62.0) 31 Ex-smoker 
(38.0)19 Curent smoker 
(28.56)60.3 Mean (SD)Smoking history, pack-years
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; SD, standard 
deviation.
(85% of patients). During the study, all patients were
randomised, and no patient received the study drug
in error; thus, the safety population was identical to
the mITT population. Forty-five (90%) patients com-
pleted the study. Five patients discontinued prema-
turely; three withdrew consent (placebo: n = 1; inda-
caterol 150 μg: n = 2), one (indacaterol 150 μg) expe-
rienced an SAE (described later under the ‘Safety’
section), and one (indacaterol 600 μg) patient’s condi-
tion no longer required any study medication.
Table 1 represents the demographics and baseline
clinical characteristics of all randomised patients. The
mean age of all patients was 67.2 years. All patients
were current or former smokers, and the majority
(92%) of them were male. Mean duration of COPD
was 2.9 years, and patients’ post-bronchodilator % pre-
dicted FEV1 at screening ranged from 31% to 78%, in-
dicating a COPD severity of moderate-to-severe inten-
sity according to the JRS COPD guidelines6 and the
GOLD guideline.5
EFFICACY
For standardised FEV1AUC22-24h, all three indacaterol
doses were statistically superior to placebo (P <
0.001), with all three doses exceeding the prespeci-
fied 120 mL criterion for minimal clinically important
difference (130 [90% CI: 100, 160], 160 [130, 190], and
170 [140, 200] mL for the indacaterol 150, 300, and
600 μg doses, respectively; Fig. 2). The 300 and 600
μg doses of indacaterol showed similar bronchodila-
tor efficacy, and both were statistically superior to the
150 μg dose (P < 0.05).
All indacaterol doses showed statistically signifi-
cantly higher peak FEV1 and significantly greater
standardised FEV1AUC0-24h than placebo (P < 0.001)
(Table 2). Serial measurements of FEV1 over 24 h are
shown in Figure 3. All indacaterol doses showed a
statistically significantly higher FEV1 than placebo
(P < 0.001) at all post-dose time points. Indacaterol
showed a fast onset of bronchodilation, with
treatment-placebo differences in FEV1 at 5 min post-
dose being 110 (90% CI: 80, 130), 120 (100, 140), and
110 (90, 130) mL for the 150, 300, and 600 μg doses,
Efficacy of Indacaterol in COPD
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Fig. 3 Adjusted mean FEV1 (a) over 24 h and (b) 0-4 h 
post-dose (modified intent-to-treat population). (  )place-
bo, (  )indacaterol 150 μg, (  )indacaterol 300 μg, and 
(  )indacaterol 600 μg. Al doses of indacaterol were supe-
rior to placebo (P < 0.001) at al time points. Study drug was 
given between 08:00-10:00 AM on Day 1 (coresponding to 
time 0). FEV1, forced expiratory volume in 1 second.
Table 2 Analysis of covariance of peak FEV1 and standardised FEV1AUC0-24h (modified intent-to-treat population)
Placebo
Indacaterol
600 μg300 μg150 μg
Peak FEV1 (L)
47484748n
1.42 (0.009)1.58 (0.009) *, **1.57 (0.009)* , **1.54 (0.009)*Least squares mean (SE)
Standardised FEV1AUC0-24h (L)
45474647n
1.32 (0.009)1.50 (0.009) *, **1.49 (0.009) *, **1.46 (0.009) *Least squares mean (SE)
AUC, area under the curve; FEV1, forced expiratory volume in 1 second; SE, standard eror.
 *P < 0.001 vs placebo; ** P < 0.05 vs indacaterol 150 μg.
respectively. All indacaterol doses had statistically
significantly higher FVC, FEF25-75%, and percent
change from period baseline in FEV1 than placebo at
all post-dose time points (P < 0.001).
SAFETY
The overall incidence of AEs was 18.8% (948), 19.1%
(947), and 25.0% (1248) with indacaterol 150, 300,
and 600 μg, respectively, as compared with 14.9% (7
47) with placebo (Table 3). The most common AE
was cough (indacaterol 150 μg: n = 4 [8.3%]; 300 μg:
n = 4 [8.5%]; 600 μg: n = 5 [10.4%]; placebo: n = 1
[2.1%]), and was mostly mild in severity and transient
in nature, occurring just after inhalation of the study
drug. One patient receiving indacaterol 150 μg expe-
rienced an SAE (subileus), which was not suspected
to be study drug related and which resolved during
follow up after study drug discontinuation. No death
was reported during the study.
The overall incidences of hypokalaemia and hyper-
glycaemia are shown in Table 4. There were no clini-
cally notable potassium values (minimum post-
baseline value: <3.0 mmolL) in any treatment group
during the study. The incidence of clinically notable
values in blood glucose levels (maximum post-
baseline value : >9.99 mmolL) for indacaterol 150 μg
(two patients) and placebo (two patients) were simi-
lar and lower than that for indacaterol 300 μg (three
patients) and 600 μg (four patients).
The incidence of abnormally high pulse rate (>90
beatsmin) was lower with indacaterol treatments
than that with placebo (Table 4). The incidences of
abnormally decreased and elevated blood pressure
findings were similar between indacaterol and pla-
cebo, with the exception of a higher incidence of ele-
vated diastolic blood pressure (>90 mm Hg) with in-
dacaterol treatments (10-17%) as compared with pla-
cebo (9%). Only one patient had a >60 ms change in
QTcF from baseline, which was observed after ad-
ministration of indacaterol 600 μg (Table 4). How-
ever, the increase was from 341 ms at baseline up to
403 ms at 4 h post-dose and up to 404 ms at 24 h post-
dose, and was regarded by the investigator to have
no clinical significance. No QTcF values above 500
ms were reported.
Kato M et al.
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Table 3 Number (%) of patients with adverse events, overal and by primary system organ class (safety population)
PlaceboIndacaterol






 7 (14.9)12 (25.0) 9 (19.1) 9 (18.8)Total 
Primary system organ 
2 (4.3) 6 (12.5) 6 (12.8)4 (8.3)Respiratory, thoracic, and mediastinal disorders
1 (2.1)1 (2.1)1 (2.1)1 (2.1)Gastrointestinal disorders
1 (2.1)2 (4.2)0    0    Infections and infestations
1 (2.1)0    1 (2.1)1 (2.1)Investigations
0    1 (2.1)0    1 (2.1)Musculoskeletal and connective tissue disorders
0    2 (4.2)0    0    Nervous system disorders
1 (2.1)1 (2.1)0    0    Cardiac disorders
0    0    1 (2.1)0    General disorders and administration site conditions
0    0    0    1 (2.1)Injury, poisoning, and procedural complications
0    0    0    1 (2.1)Metabolism and nutritional disorders
1 (2.1)1 (2.1)1 (2.1)1 (2.1)Vascular disorders
Table 4 Overal incidence of hypokalaemia, hyperglycaemia, abnormal values of pulse rate and blood pressure, and notable 
QTc values (safety population)
PlaceboIndacaterol
(N = 47)600 μg (N = 48)
300 μg
 (N = 47)
150 μg
 (N = 48)
n (%)
Serum potassium: minimum post-baseline value †
0    2 (4.2)0    1 (2.1)Below lower limit of normal range
0    0    0    0    Clinicaly notable ‡
Blood glucose: maximum post-baseline value †
36 (76.6)38 (79.2)37 (78.7)37 (77.1)Above upper limit of normal range
2 (4.5)4 (8.5)3 (6.5)2 (4.3)Clinicaly notable ‡
Pulse rate: maximum post-baseline value §
10 (21.3) 8 (16.7) 9 (19.1) 8 (16.7)Above 90 bpm
Systolic blood pressure: maximum post-baseline value ¶
10 (21.3) 9 (18.8)11 (23.4) 9 (18.8)Above 140 mmHg
Diastolic blood pressure: minimum post-baseline value ¶
4 (8.5) 8 (16.7) 5 (10.6) 5 (10.4)Above 90 mmHg
QTc interval (Fridericia’ sformula) ¶ ¶
Absolute values
0    0    1 (2.1)0    >450 ms (males)
0    0    0    0    >470 ms (females)
Change from baseline
0    0    0    2 (4.2)30-60 ms
0    1 (2.1)0    0     >60 ms
† Measurement of serum potassium and blood glucose levels were taken pre-dose and at 15 min, 1 h, 4 h, and 24 h post-dose for each 
treatment.
‡ Clinicaly notable values are those outside the folowing limits: potassium, <3 mmol/L; glucose, >9.99 mmol/L.
§ Measurement of pulse rate was taken pre-dose and at 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, 22 h, 23 h, and 24 h post-dose for each 
treatment.
¶ Measurement of blood pressure was taken pre-dose and at 15 min, 1 h, 4 h, 12 h and 24 h post-dose for each treatment.
¶ ¶ ECG was recorded pre-dose and at 1 h, 4 h, and 24 h post-dose for each treatment.
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DISCUSSION
Clinical practice guidelines recommend treatment
with one or more different classes of long-acting
bronchodilators in patients with moderate-to-severe
COPD.5,6 Poor adherence to treatment with long-
acting bronchodilators may significantly hinder the
attainment of optimal efficacy. Currently marketed
LABAs, namely, formoterol and salmeterol, are both
administered twice daily. Indacaterol is the first ultra-
LABA with a once-daily dosing regimen. Once-daily
regimens have advantages in terms of patient accept-
ability and convenience, and therefore improved ad-
herence to therapy.26,27 The availability of an effective
once-daily ultra-LABA could provide a useful addition
to treatment options for COPD.
This study was designed to assess the bronchodila-
tor efficacy and safety of single doses of indacaterol
(150, 300, and 600 μg) in Japanese patients with
COPD. A crossover design (rather than a parallel-
group design) was chosen, because within-patient
variability in FEV1 was expected to be less than
between-patient variability.
The primary efficacy analysis showed that all inda-
caterol doses were associated with statistically signifi-
cantly greater standardised FEV1AUC22-24h than pla-
cebo, with differences exceeding the prespecified
minimal clinically important difference of 120 mL22,23
(130, 160, and 170 mL for indacaterol 150, 300, and
600 μg, respectively); furthermore, the correspond-
ing 90% CIs were relatively narrow, indicating the pre-
cision of the estimated differences. Although, all
doses were associated with clinically relevant bron-
chodilation, indacaterol 300 and 600 μg provided simi-
lar values for FEV1AUC22-24h, and both were statisti-
cally superior to indacaterol 150 μg. This suggests
that the efficacy of indacaterol might reach a plateau
at a dose of 300 μg once daily.
The results of the primary analysis were supported
by the other efficacy analyses, further indicating that
all indacaterol doses had statistically significantly
higher peak FEV1 and greater standardised FEV1
AUC0-24h than that of placebo. All indacaterol doses
showed improvement in FEV1 as early as 5 min post-
dose, which was thereafter sustained for 24 h, a find-
ing similar to that observed in the Caucasian popula-
tion.18,20
Given the similar efficacy and safety demonstrated
by indacaterol in Japanese and Caucasian patients,
this is an indication that indacaterol is likely to be ef-
fective in the management of COPD regardless of a
patient’s ethnicity. This is an important consideration
for any bronchodilator, as there is evidence of a possi-
ble relationship between ethnicity and clinical, physi-
ological, and radiological phenotypes of COPD,28,29
which may impact a drug’s efficacy.
In this study, for all treatment groups there was an
increase in FEV1 from 22 h to 24 h post-dose, a profile
similar to that seen in previous indacaterol studies in
patients with COPD.18,20 Since this increase was also
observed in the placebo group, this effect is likely
due to diurnal variation in lung function, and not a
true effect of indacaterol. Such diurnal variation is an-
ticipated in patients with COPD, as sleep has negative
effects on respiration and gas exchange.30 It is of
note, therefore, that the efficacy of indacaterol was
maintained at these time points.
In terms of overall safety, all doses of indacaterol in
this study were safe and well tolerated and showed a
favourable safety profile in Japanese patients with
moderate-to-severe COPD. Most of the AEs observed
were expected in the patient population studied and
were similar to those seen in previous studies of inda-
caterol conducted in the Caucasian population.18,19
Class-related side effects of inhaled beta2-agonists in-
clude tachycardia, hypokalaemia, and hyperglycae-
mia, which are believed to be due to systemic absorp-
tion, resulting in the activation of beta-2 adrenocep-
tors located in various organs.31-33 In the present
study, there were no unexpected effects on clinical
laboratory parameters, with no clear relationship be-
tween the incidence of hypokalaemia or hyperglycae-
mia and indacaterol dose. Furthermore, the inci-
dences of abnormally high pulse rate or blood pres-
sure was similar for both indacaterol and placebo.
ECG evaluations showed no marked difference be-
tween the active treatments and placebo in terms of
effects on the QT interval, with no relationship be-
tween notable QTc interval values and indacaterol
dose. This favourable cardiac safety profile is impor-
tant, given the high levels of cardiac comorbidities in
patients with COPD.34-36 Longer-term safety studies
of indacaterol are currently ongoing in the Japanese
population.
In conclusion, once-daily dosing of indacaterol 150,
300, and 600 μg delivered via an SDDPI provided ef-
fective bronchodilation in Japanese patients with
moderate-to-severe COPD, with sustained 24-h bron-
chodilator efficacy and a fast onset of action. These
findings are similar to those observed in the Cauca-
sian population, indicating the ethnic insensitivity of
indacaterol. All doses of indacaterol were well toler-
ated with a good overall safety profile and showed no
meaningful effects on the cardiovascular class-related
side effects of beta2-agonists in the Japanese popula-
tion. Indacaterol could, therefore, be a useful treat-
ment option for Japanese patients with COPD.
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